Rocket Pharmaceuticals Sells $180M Rare Disease Review Voucher, Extends Cash Runway to 2028
Rocket Pharmaceuticals has agreed to sell its Rare Pediatric Disease Priority Review Voucher for $180 million following FDA accelerated approval of KRESLADI. The transaction boosts non-dilutive capital and extends the company's cash runway into Q2 2028 to advance cardiovascular gene therapy programs targeting Danon disease, PKP2-ACM and BAG3-DCM.
1. PRV Sale Agreement
Rocket Pharmaceuticals has entered a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $180 million following FDA accelerated approval of KRESLADI (marnetegragene autotemcel).
2. Impact on Financial Position
Proceeds from the PRV sale provide non-dilutive capital that extends Rocket’s cash runway into the second quarter of 2028, supporting ongoing operations without issuing new equity.
3. Support for Gene Therapy Pipeline
The funds will be allocated to advance Rocket’s prioritized cardiovascular gene therapy programs, including clinical-stage treatments targeting Danon disease, PKP2-ACM and BAG3-DCM, reinforcing progress toward key clinical milestones.